Alivus Life

What does Alivus Life do?

Alivus Life Sciences Ltd is a mid-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 650 Cr and a net profit of 142 Cr for the quarter ending March 2025. Key metrics include a P/E ratio of 26.00 and a market cap of Rs 12,350 Cr.

Overview: <BR>Alivus Life Sciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History: <BR>Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited' in 2011. The company was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 650 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 142 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 12,350 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.17 <BR>Return on Equity: 19.13% <BR>Price to Book: 4.91 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Has Alivus Life declared dividend?

Alivus Life Sciences Ltd has declared a 1125% dividend, amounting to 22.5 per share, with an ex-date of October 17, 2023. Despite the significant dividend declaration, the dividend yield is 0%, and total returns have varied, showing strong performance over longer periods but negative returns in the last 6 months.

Alivus Life Sciences Ltd has declared a 1125% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1125%<BR>- Amount per share: 22.5<BR>- Ex-date: Oct-17-2023<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.81%, with a dividend return of 0%, resulting in a total return of -4.81%.<BR><BR>Over the past year, the price return was 18.32%, with a dividend return of 0%, leading to a total return of 18.32%.<BR><BR>In the 2-year period, the price return was 84.65%, the dividend return was 3.79%, and the total return was 88.44%.<BR><BR>For the 3-year period, the price return was 119.17%, the dividend return was 12.28%, resulting in a total return of 131.45%.<BR><BR>In the 4-year period, there was no price return, no dividend return, and a total return of 0.0%.<BR><BR>Over the last 5 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, Alivus Life has declared a significant dividend, but the dividend yield remains at 0%. The total returns show a mixed performance, with strong returns over longer periods but negative returns in the shorter term.

Who are the peers of the Alivus Life?

Alivus Life's peers include Natco Pharma, Sai Life, Blue Jet Health, Caplin Point Lab, Sanofi India, and others. Alivus Life has a 1-year return of 24.47%, with management risk rated as Good, while Blue Jet Health leads with a 128.90% return.

Peers: The peers of Alivus Life are Natco Pharma, Sai Life, Blue Jet Health, Caplin Point Lab, Sanofi India, Sanofi Consumer, Granules India, Marksans Pharma, P & G Health Ltd, and Acutaas Chemical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi India and P & G Health Ltd, while Good management risk is found at Natco Pharma, Blue Jet Health, Caplin Point Lab, Alivus Life, Granules India, Marksans Pharma, and the rest. Average management risk is noted at Sai Life and Acutaas Chemical, while Sanofi Consumer does not qualify. Growth is rated as Good for Natco Pharma, Sai Life, and the rest, while Below Average growth is seen at Blue Jet Health, Sanofi India, Alivus Life, Granules India, Marksans Pharma, and P & G Health Ltd. Capital Structure is Excellent for Natco Pharma, Blue Jet Health, Caplin Point Lab, Sanofi India, Alivus Life, Granules India, Marksans Pharma, P & G Health Ltd, and the rest, while Good is noted for Sai Life and Acutaas Chemical, and Sanofi Consumer does not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Blue Jet Health at 128.90%, while Sanofi India has the lowest at -7.90%. Alivus Life's 1-year return is 24.47%, which is significantly higher than Sanofi India's but lower than Blue Jet Health's. Additionally, the peers with negative six-month returns include Sanofi India, Caplin Point Lab, and Granules India.

Who are in the management team of Alivus Life?

As of March 2023, the management team of Alivus Life includes Glenn Saldanha (Chairman), V S Mani, Yasir Yusufali Rawjee (Managing Director & CEO), Vinod Naik, and four independent non-executive directors: Sridhar Gorthi, Manju Agarwal, Taruvai Laxminarayanan Easwar, and Gita Nayyar. This team offers a diverse range of expertise and leadership.

As of March 2023, the management team of Alivus Life includes the following individuals:<BR><BR>1. Glenn Saldanha - Chairman & Non Executive Director<BR>2. V S Mani - Non Executive Director<BR>3. Yasir Yusufali Rawjee - Managing Director & CEO<BR>4. Vinod Naik - Executive Director & Wholetime Director<BR>5. Sridhar Gorthi - Independent Non Executive Director<BR>6. Manju Agarwal - Independent Non Executive Director<BR>7. Taruvai Laxminarayanan Easwar - Independent Non Executive Director<BR>8. Gita Nayyar - Independent Non Executive Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

Who are the top shareholders of the Alivus Life?

The top shareholders of Alivus Life include Nirma Limited with 74.99%, followed by 71 Foreign Institutional Investors holding 6.57%, and 18 mutual fund schemes at 3.59%. Individual investors own 10.5%, while Polar Capital Funds Plc - Healthcare Opportunities is the largest public shareholder with 2.79%.

The top shareholders of Alivus Life include Nirma Limited, which holds the largest stake at 74.99%. Other significant shareholders are 71 Foreign Institutional Investors (FIIs) with a combined holding of 6.57%, and 18 mutual fund schemes that account for 3.59%. Additionally, Polar Capital Funds Plc - Healthcare Opportunities is the highest public shareholder, holding 2.79%. Individual investors collectively own 10.5% of the company.

How big is Alivus Life?

As of 24th July, Alivus Life Sciences Ltd has a market capitalization of 12,664.00 Cr, with recent net sales of 2,386.89 Cr and net profit of 485.63 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Alivus Life Sciences Ltd has a market capitalization of 12,664.00 Cr, categorizing it as a Mid Cap company. <BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,386.89 Cr, while the sum of Net Profit for the same period is 485.63 Cr. <BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2024. Shareholder's Funds are valued at 2,332.32 Cr, and Total Assets amount to 2,850.41 Cr.

How has been the historical performance of Alivus Life?

Alivus Life has shown consistent growth over the past six years, with net sales increasing from 1,537.31 Cr in March 2020 to 2,386.88 Cr in March 2025, and profit after tax rising from 313.10 Cr to 485.63 Cr. Total assets also grew significantly from 1,725.60 Cr to 3,411.45 Cr, reflecting a strong expansion strategy.

Answer:<BR>The historical performance of Alivus Life shows a consistent growth trend in net sales and profits over the past six years, culminating in a profit after tax of 485.63 Cr for the year ending March 2025.<BR><BR>Breakdown:<BR>Alivus Life has demonstrated a steady increase in net sales, rising from 1,537.31 Cr in March 2020 to 2,386.88 Cr in March 2025. The total operating income followed a similar trajectory, reaching 2,386.88 Cr in March 2025, up from 1,537.31 Cr in March 2020. Operating profit, excluding other income, also saw growth, increasing from 471.96 Cr in March 2020 to 682.58 Cr in March 2025. The profit before tax reached 654.13 Cr in March 2025, while profit after tax increased from 313.10 Cr in March 2020 to 485.63 Cr in March 2025. The company's total assets grew significantly from 1,725.60 Cr in March 2020 to 3,411.45 Cr in March 2025, reflecting a robust expansion strategy. Meanwhile, total liabilities increased from 1,725.60 Cr to 3,411.45 Cr over the same period, indicating a proportional rise in obligations alongside asset growth. Cash flow from operating activities showed a positive trend, although the net cash outflow in March 2025 was -230.00 Cr, down from a net inflow of 17.00 Cr in March 2024. Overall, Alivus Life's financial metrics indicate a strong upward trajectory in both revenue and profitability, despite some fluctuations in cash flow.

Are Alivus Life latest results good or bad?

Alivus Life Sciences' latest Q2 FY26 results show a 9.02% year-on-year net profit increase to ₹121.54 crores, but a significant 14.32% decline from the previous quarter, alongside a 7.34% revenue drop. Overall, while there are some positive year-on-year trends, the sequential declines and margin compression indicate a challenging environment for the company.

Alivus Life Sciences' latest results for Q2 FY26 present a mixed picture. On one hand, the company reported a net profit of ₹121.54 crores, which is a 9.02% increase year-on-year. This indicates some positive growth compared to the same quarter last year. However, the net profit saw a significant decline of 14.32% compared to the previous quarter, which raises concerns about its short-term performance.<BR><BR>Similarly, revenue for the quarter was ₹601.85 crores, reflecting a 2.25% increase year-on-year but a more troubling 7.34% decrease from the prior quarter. This sequential drop in revenue is indicative of operational challenges the company is facing.<BR><BR>Moreover, the operating margin decreased to 28.63%, down 192 basis points from the previous quarter, signaling a decline in operational efficiency. The profit after tax margin also contracted to 20.19%, further highlighting the pressure on profitability.<BR><BR>In summary, while there are some year-on-year improvements, the sequential declines in both revenue and profit, along with margin compression, suggest that the latest results are concerning and reflect a challenging environment for Alivus Life Sciences. Investors should closely monitor the company's performance in the upcoming quarters to gauge whether these trends will continue.

Is Alivus Life technically bullish or bearish?

As of December 2, 2025, the market trend has shifted to a moderately strong bearish stance, indicated by bearish MACD, moving averages, and KST on the weekly chart, along with bearish Bollinger Bands, while the RSI and Dow Theory show no immediate reversal signals.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily timeframe, and a bearish KST on the weekly chart. The Bollinger Bands are also indicating a bearish trend on the weekly timeframe. Overall, the lack of significant signals from the RSI and Dow Theory suggests a continuation of the bearish sentiment without any immediate reversal signals.

Is Alivus Life overvalued or undervalued?

As of December 4, 2025, Alivus Life is considered an attractive investment due to its undervalued status with a PE ratio of 20.10, strong operational efficiency indicated by a ROCE of 27.80% and ROE of 17.59%, and a favorable PEG ratio of 0.80 compared to peers, despite a year-to-date stock performance lagging behind the Sensex.

As of 4 December 2025, Alivus Life has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, with a PE ratio of 20.10, a Price to Book Value of 3.53, and an EV to EBITDA of 13.60. In comparison to peers, Alivus Life's PEG ratio of 0.80 suggests it is more favorably priced relative to growth than competitors like Sun Pharma, which has a PE of 37.78, and Divi's Lab, with a PE of 68.56.<BR><BR>Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -12.15% compared to the Sensex's 9.12%, the strong ROCE of 27.80% and ROE of 17.59% indicate robust operational efficiency. Overall, the metrics suggest that Alivus Life is positioned well within the pharmaceuticals and biotechnology sector, making it an attractive investment opportunity.

Should I buy, sell or hold Alivus Life Sciences Ltd?

When is the next results date for Alivus Life Sciences Ltd?

The next results date for Alivus Life Sciences Ltd is 22 January 2026.

The next results date for Alivus Life Sciences Ltd is scheduled for 22 January 2026.

Which are the latest news on Alivus Life?

Why is Alivus Life Sciences Ltd falling/rising?

As of 20-Jan, Alivus Life Sciences Ltd is experiencing a decline in its stock price, currently at 866.75, reflecting a bearish trend with a total decline of -2.33% over the last three days. The stock has underperformed significantly compared to the market, with a one-year return of -21.91%, and concerns about weak long-term growth prospects are contributing to its falling price.

As of 20-Jan, Alivus Life Sciences Ltd is experiencing a decline in its stock price, currently at 866.75, which reflects a change of -3.55 (-0.41%). The stock has been on a downward trend, having fallen for the last three consecutive days, resulting in a total decline of -2.33% during this period. Additionally, the stock is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>The stock's performance over various periods shows a significant underperformance compared to the broader market. Over the past year, Alivus has generated a return of -21.91%, while the Sensex has increased by 6.63%. This stark contrast highlights the company's struggles in the market. Furthermore, the stock is currently close to its 52-week low, being only 4.57% away from Rs 827.1.<BR><BR>Despite some positive factors, such as a high return on equity (ROE) of 18.73% and a low debt-to-equity ratio, the company's long-term growth prospects appear weak. Net sales have only grown at an annual rate of 4.84%, and operating profit has increased at a mere 2.21% over the last five years. These figures contribute to a perception of poor growth potential, which may deter investors.<BR><BR>Overall, the combination of recent price declines, underperformance relative to the market, and concerns about long-term growth prospects are contributing to the falling stock price of Alivus Life Sciences Ltd.